Rhythm Pharmaceuticals (RYTM) P/E ratio
There is no P/E ratio history on record here for Rhythm Pharmaceuticals (RYTM). Figures as of 18 Nov 2026, 05:06 UTC, from the company's filings with the SEC and Yahoo Finance.
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Not enough data
A history of P/E ratio needs at least 3 fiscal years; none is on record here for Rhythm Pharmaceuticals. Nothing is estimated to fill the gap. What is on record is in the table below.
Rhythm Pharmaceuticals P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | $107.04 | -$3.11 | |
| 2024 | — | — | $55.98 | -$4.34 | |
| 2023 | — | — | $45.97 | -$3.20 | |
| 2022 | — | — | $29.12 | -$3.47 | |
| 2021 | — | — | $9.98 | -$1.40 | |
| 2020 | — | — | $29.73 | -$3.04 | |
| 2019 | — | — | $22.96 | -$3.86 | |
| 2018 | — | — | $26.88 | — | |
| 2017 | — | — | $29.06 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
P/E ratio at health care companies of similar size
| Company | P/E ratio |
|---|---|
| PACS Group PACS | 27.9× |
| Kiniksa Pharmaceuticals International KNSA | 71.5× |
Price over the last twelve months' earnings per share, as the market data feed reports it.
Rhythm Pharmaceuticals, figure by figure
- Rhythm Pharmaceuticals market cap
- Rhythm Pharmaceuticals revenue
- Rhythm Pharmaceuticals earnings
- Rhythm Pharmaceuticals earnings per share (EPS)
- Rhythm Pharmaceuticals P/S ratio
- Rhythm Pharmaceuticals P/B ratio
- Rhythm Pharmaceuticals free cash flow
- Rhythm Pharmaceuticals operating margin
- Rhythm Pharmaceuticals dividend
- Rhythm Pharmaceuticals shares outstanding
- Rhythm Pharmaceuticals total debt
- Rhythm Pharmaceuticals cash on hand
- Rhythm Pharmaceuticals total assets
- Rhythm Pharmaceuticals return on equity (ROE)
- Rhythm Pharmaceuticals return on invested capital (ROIC)
Rhythm Pharmaceuticals (RYTM) overview: price, valuation and scorecardAll health care companies by market value
Rhythm Pharmaceuticals P/E ratio: questions and answers
How is Rhythm Pharmaceuticals's P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Rhythm Pharmaceuticals (RYTM) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/RYTM/pe-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.